Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105:295–309. https://doi.org/10.1159/000475526.

Article  CAS  PubMed  Google Scholar 

Lehrman ED, Fidelman N. Liver-directed therapy for neuroendocrine tumor liver metastases in the era of peptide receptor radionuclide therapy. Semin Intervent Radiol. 2020;37:499–507. https://doi.org/10.1055/s-0040-1720951.

Article  PubMed  PubMed Central  Google Scholar 

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Strosberg JR, Caplin ME, Kuz PL, Ruszniewski PB, Bodei L, Hendifar AE, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NEETER-1): final overall survival and long-term safety results from an open-label, randomized, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–63. https://doi.org/10.1016/S1470-2045(21)00572-6. Long-term follow-up study to NETTER-1 trial, which showed no overall survival benefit for patients WD-NET who were treated with PRRT.

Article  CAS  PubMed  Google Scholar 

Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40:69–80. https://doi.org/10.1007/s00270-016-1478-z.

Article  PubMed  Google Scholar 

• Wong TY, Zhang KS, Gandhi RT, Collins ZS, O’Hara R, Wang EA, et al. Long-term outcomes following 90Y radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer. 2022;22:224. https://doi.org/10.1186/s12885-022-09302-z. Prospective registry data that documented safety of 90Y radioembolization for patients with WD-NET.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol. 2019;30:1915–23. https://doi.org/10.1016/j.jvir.2019.06.003.

Article  PubMed  Google Scholar 

Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29:858–65. https://doi.org/10.1016/j.jvir.2018.02.002.

Article  PubMed  Google Scholar 

Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. Semin Radiat Oncol. 2018;28:321–31. https://doi.org/10.1016/j.semradonc.2018.06.007.

Article  PubMed  PubMed Central  Google Scholar 

Sangro B, Martínez-Urbistondo D, Beste L, Bilbao J, Coldwell D, Flamen P, et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology. 2017;66:969–82. https://doi.org/10.1002/hep.29207.

Article  PubMed  Google Scholar 

Hope TA, Pavel M, Bergsland EK. Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time? J Clin Oncol. 2022;40:2818–29. https://doi.org/10.1200/JCO.22.00176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riff BP, Yang YX, Soulen MC, Pryma DA, Bennett B, Wild D, et al. Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors. Clin Nucl Med. 2015;40:845–50. https://doi.org/10.1097/RLU.0000000000000935.

Article  PubMed  Google Scholar 

Hamiditabar M, Ali M, Bolek L, Vahdati G, Tworowska I, Delpassand ES. Safety and effectiveness of 177Lu-DOTATATE peptide receptor radionuclide therapy after regional hepatic embolization in patients with somatostatin-expressing neuroendocrine tumors. Clin Nucl Med. 2017;42:822–8. https://doi.org/10.1097/RLU.0000000000001818.

Article  PubMed  Google Scholar 

Braat AJAT, Ahmadzadehfar H, Kappadath SC, Stothers CL, Frilling A, Deroose CM, et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43:246–53. https://doi.org/10.1007/s00270-019-02350-2.

Article  CAS  PubMed  Google Scholar 

Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663–9. https://doi.org/10.2967/jnumed.112.107482.

Article  CAS  PubMed  Google Scholar 

Devulapalli KK, Fidelman N, Soulen MC, Miller M, Johnson MS, Addo E, et al. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology. 2018;288:774–81. https://doi.org/10.1148/radiol.2018170962.

Article  PubMed  Google Scholar 

Soulen M, White S, Fidelman N, Garcia-Monaco R, Wileyto E, Avritscher R, et al. Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET): first safety report. J Vasc Intervent Radiol. 2019;2019(30):S49-50. https://doi.org/10.1016/j.jvir.2018.12.151.

Article  Google Scholar 

Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19:390. https://doi.org/10.1186/s13063-018-2782-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiation Oncology Biol Phys. 2011;79:163–71. https://doi.org/10.1016/j.ijrobp.2009.10.062.

Article  Google Scholar 

Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7:843–50. https://doi.org/10.1016/S2468-1253(22)00091-7.

Article  PubMed  Google Scholar 

Padia SA, Johnson GE, Agopian VG, DiNorcia J, Srinivasa RN, Sayer J, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123:172–8. https://doi.org/10.1002/jso.26223.

Article  PubMed  Google Scholar 

• Soulen MC, Teitelbaum UR, Mick R, Eads J, Mondschein JI, Dagli M, et al. Integration of radioembolization with CapTem for liver-dominant G2 NETs: long-term outcomes. Endocr Abstr. 2022;89:C17. https://doi.org/10.1530/endoabs.89.C17. Retrospective single-center study demonstrated that 90Y radioembolization in combination with capecitabine and temozolomide regimen for patients with WHO grade 2 NET is safe and resulted in higher than expected hepatic progression-free survival.

Article  Google Scholar 

Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, et al. Present and future of immunotherapy in neuroendocrine tumors. Rev Endocr Metab Disord. 2021;22:615–36. https://doi.org/10.1007/s11154-021-09647-z.

Article  PubMed  PubMed Central  Google Scholar 

Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers (Basel). 2019;11:1085. https://doi.org/10.3390/cancers11081085.

Article  CAS  PubMed  Google Scholar 

Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104. https://doi.org/10.1186/s13045-018-0647-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fidelman N, Le L, Fong L, Zhang L, Bergsland EK, A pilot study of pembrolizumab and liver-directed therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive liver metastases. NANETS 2018 Symposium Abstracts. 2018. https://nanets.net/abstracts-archive/2018/953-abstract-t2/file

Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, et al. Periprocedural management of patients undergoing liver resection or embolotherapy for neuroendocrine tumor metastases. Pancreas. 2019;48:496–503. https://doi.org/10.1097/MPA.0000000000001271.

Article  PubMed  Google Scholar 

Kratochwil C, Giesel FL, López-Benítez R, Schimpfky N, Kunze K, Eisenhut M, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16:2899–905. https://doi.org/10.1158/1078-0432.CCR-10-0004.

Article  CAS  PubMed  Google Scholar 

Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, et al. Intraarterial peptide receptor radionuclide therapy using 90 Y-DOTATOC for hepatic metastases of neuroendocrine tumors. J Nucl Med. 2020;2021(62):221–7. https://doi.org/10.2967/jnumed.119.241273.

Article  CAS  Google Scholar 

Kratochwil C, López-Benítez R, Mier W, Haufe S, Isermann B, Kauczor HU, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18:595–602. https://doi.org/10.1530/ERC-11-0144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials. 2020;21:141. https://doi.org/10.1186/s13063-019-3888-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Vidal-Jove J, Serres X, Vlaisavljevich E, Cannata J, Duryea A, Miller R, et al. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperthermia. 2022;39:1115–23. https://doi.org/10.1080/02656736.2022.2112309. First in man study of histotripsy for treatment of malignant liver tumors.

Article  PubMed  Google Scholar 

Wah TM, Pech M, Thormann M, Serres X, Littler P, Stenberg B, et al. A multi-centre, single arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the HistoSonics system in the treatment of primary and metastatic liver cancers (#HOPE4LIVER). Cardiovasc Intervent Radiol. 2023;46:259–67. https://doi.org/10.1007/s00270-022-03309-6.